• Home
  • About
  • Drug Development Pipeline
  • News
  • Investors
  • Careers
  • Contact
  • TSX.V: RKV
  • FSE: 7JO0
  • OTCMKTS: RKVTF

Rakovina Therapeutics Secures Exclusivity on Optimized kt-5000 Lead Profile from Variational AI

by Rakovina Therapeutics | Oct 14, 2026 | Uncategorized

DOWNLOAD Agreement provides Rakovina exclusive access to its optimized kt-5000 target profile and extends AI-powered lead optimization through year-end at no additional cost VANCOUVER, British Columbia, October 14, 2026 (GLOBE NEWSWIRE) – Rakovina Therapeutics Inc....

Rakovina Therapeutics Partners with Boston-based Celvion Therapeutics to Leverage AI and Real-World Clinical Data for Precision Cancer Drug Development

by Rakovina Therapeutics | Oct 1, 2026 | Uncategorized

DOWNLOAD Collaboration to identify optimal combination therapies, predictive biomarkers and patient populations for Rakovina’s ATR inhibitor program VANCOUVER, British Columbia, October 1, 2026 (GLOBE NEWSWIRE) – Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0)...

Rakovina Therapeutics Announces Appointment of New Scientific Advisory Board Member

by Rakovina Therapeutics | Sep 18, 2026 | Uncategorized

DOWNLOAD Yale physician-scientist and biotech entrepreneur Dr. Ranjit Bindra brings deep expertise in DNA repair, synthetic lethality and brain tumor therapeutics VANCOUVER, British Columbia, September 17, 2026 (GLOBE NEWSWIRE) – Rakovina Therapeutics Inc. (TSX-V:...

Rakovina Therapeutics Announces Appointment of Professor Petra Hamerlik to its Board of Directors 

by Rakovina Therapeutics | Sep 10, 2026 | Uncategorized

DOWNLOAD Chair of Translational Neuro-Oncology at the University of Manchester, previously a member of the Company’s Scientific Advisory Board, elected at the 2026 Annual General Meeting VANCOUVER, British Columbia, September 10, 2026 (GLOBE NEWSWIRE) —...

 Rakovina Therapeutics Announces Final Closing of Upsized Non-Brokered Private Placement

by Rakovina Therapeutics | Aug 31, 2026 | Uncategorized

DOWNLOAD Financing completed at the full upsized amount following strong investor demand VANCOUVER, British Columbia, August 31, 2026 (GLOBE NEWSWIRE) — Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing innovative cancer...

Rakovina Therapeutics Announces Results from 2026 Annual General Meeting

by Rakovina Therapeutics | Aug 31, 2026 | Uncategorized

VANCOUVER, British Columbia, August 19, 2026 (GLOBE NEWSWIRE) — Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing innovative cancer therapies through AI-powered drug discovery, is pleased to announce the results of voting...
« Older Entries

Suite 720, 999 West Broadway, Vancouver, British Columbia
Canada V5Z 1K5

Home

About

Drug Development Pipeline

News

Investors

Careers

Contact

Company Disclosure

Privacy Policy

Subscribe

To Receive Company Updates

Copyright ©2020-2026 Rakovina Therapeutics Inc. All rights reserved.  | Privacy Policy | Terms of Use |  Site by Vanooms Media